Curcumin's Effects on Alzheimer's Disease in Mice
Author Information
Author(s): Cade Shaun, Prestidge Clive, Zhou Xin‐Fu, Bobrovskaya Larisa
Primary Institution: University of South Australia
Hypothesis
Does a bioavailable curcumin formulation alter Alzheimer's disease pathologies in a mouse model?
Conclusion
The bioavailable curcumin formulation did not reduce amyloid plaques and may have aggravated neuroinflammation.
Supporting Evidence
- The curcumin formulation did not change the number or size of amyloid plaques in the brain.
- Curcumin increased GFAP protein levels, indicating potential neuroinflammation.
- Previous studies showed curcumin's effectiveness in reducing amyloid plaques, but this study did not replicate those findings.
Takeaway
Researchers tested a special curcumin drink on mice with Alzheimer's, but it didn't help with the brain problems and might have made things worse.
Methodology
Mice were treated with a curcumin formulation, and their brains were analyzed for amyloid plaques and neuroinflammation.
Potential Biases
Potential bias due to the authors' involvement in the development of the curcumin formulation.
Limitations
The study focused mainly on amyloid pathology and did not assess cognitive performance.
Participant Demographics
Male and female APPswe/PS1dE9 mice were used as the Alzheimer's model.
Statistical Information
P-Value
p=0.0036
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website